91 related articles for article (PubMed ID: 8238887)
21. Cyclopentenylcytosine triphosphate. Formation and inhibition of CTP synthetase.
Kang GJ; Cooney DA; Moyer JD; Kelley JA; Kim HY; Marquez VE; Johns DG
J Biol Chem; 1989 Jan; 264(2):713-8. PubMed ID: 2910861
[TBL] [Abstract][Full Text] [Related]
22. The pyrimidin analogue cyclopentenyl cytosine induces alloantigen-specific non-responsiveness of human T lymphocytes.
Nikolaeva N; Bemelman FJ; Yong SL; Verschuur A; van Lier RA; ten Berge IJ
Clin Exp Immunol; 2008 Feb; 151(2):348-58. PubMed ID: 18062797
[TBL] [Abstract][Full Text] [Related]
23. Mechanism of resistance to cyclopentenyl cytosine (CPE-C) in Molt-4 lymphoblasts.
Blaney SM; Grem JL; Balis FM; Cole DE; Adamson PC; Poplack DG
Biochem Pharmacol; 1993 Apr; 45(7):1493-501. PubMed ID: 8471071
[TBL] [Abstract][Full Text] [Related]
24. In vitro inhibition of cytidine triphosphate synthetase activity by cyclopentenyl cytosine in paediatric acute lymphocytic leukaemia.
Verschuur AC; Van Gennip AH; Leen R; Meinsma R; Voute PA; van Kuilenburg AB
Br J Haematol; 2000 Jul; 110(1):161-9. PubMed ID: 10930994
[TBL] [Abstract][Full Text] [Related]
25. Reversed-phase high-performance liquid chromatographic determination of the new antitumor agent cyclopentenyl cytosine in biological fluids.
Hegedus L; Ford H; Hartman NR; Kelley JA
J Chromatogr B Biomed Sci Appl; 1997 Apr; 692(1):169-79. PubMed ID: 9187397
[TBL] [Abstract][Full Text] [Related]
26. CPEC induces erythroid differentiation of human myeloid leukemia K562 cells through CTP depletion and p38 MAP kinase.
Huang M; Wang Y; Collins M; Graves LM
Leukemia; 2004 Nov; 18(11):1857-63. PubMed ID: 15385935
[TBL] [Abstract][Full Text] [Related]
27. Quantitation of intracellular triphosphate of emtricitabine in peripheral blood mononuclear cells from human immunodeficiency virus-infected patients.
Darque A; Valette G; Rousseau F; Wang LH; Sommadossi JP; Zhou XJ
Antimicrob Agents Chemother; 1999 Sep; 43(9):2245-50. PubMed ID: 10471573
[TBL] [Abstract][Full Text] [Related]
28. Phase I clinical trial of continuous infusion cyclopentenyl cytosine.
Politi PM; Xie F; Dahut W; Ford H; Kelley JA; Bastian A; Setser A; Allegra CJ; Chen AP; Hamilton JM
Cancer Chemother Pharmacol; 1995; 36(6):513-23. PubMed ID: 7554044
[TBL] [Abstract][Full Text] [Related]
29. Limited antitumor-effect associated with toxicity of the experimental cytotoxic drug cyclopentenyl cytosine in NOD/scid mice with acute lymphoblastic leukemia.
Schimmel KJ; Nijmeijer BA; van Schie ML; Falkenburg JH; Guchelaar HJ
Leuk Res; 2007 Nov; 31(11):1545-51. PubMed ID: 17459472
[TBL] [Abstract][Full Text] [Related]
30. Intracellular nucleoside triphosphate concentrations in HIV-infected patients on dual nucleoside reverse transcriptase inhibitor therapy.
Moore JD; Acosta EP; Johnson VA; Bassett R; Eron JJ; Fischl MA; Long MC; Kuritzkes DR; Sommadossi JP
Antivir Ther; 2007; 12(6):981-6. PubMed ID: 17926654
[TBL] [Abstract][Full Text] [Related]
31. Formulation, quality control and shelf life of the experimental cytostatic drug cyclopentenyl cytosine.
Schimmel K; Guchelaar HJ; van Kan E
Drug Dev Ind Pharm; 2006 Apr; 32(4):497-503. PubMed ID: 16638688
[TBL] [Abstract][Full Text] [Related]
32. Cyclopentenyl cytosine primes SK-N-BE(2)c neuroblastoma cells for cytarabine toxicity.
Bierau J; Van Gennip AH; Leen R; Helleman J; Caron HN; Van Kuilenburg AB
Int J Cancer; 2003 Jan; 103(3):387-92. PubMed ID: 12471622
[TBL] [Abstract][Full Text] [Related]
33. Increased cytotoxicity of 2',2'-difluoro-2'-deoxycytidine in human leukemic cell-lines after a preincubation with cyclopentenyl cytosine.
Verschuur AC; Van Gennip AH; Leen R; Van Kuilenburg AB
Nucleosides Nucleotides Nucleic Acids; 2004 Oct; 23(8-9):1517-21. PubMed ID: 15571289
[TBL] [Abstract][Full Text] [Related]
34. Specificity enhancement with LC-positive ESI-MS/MS for the measurement of nucleotides: application to the quantitative determination of carbovir triphosphate, lamivudine triphosphate and tenofovir diphosphate in human peripheral blood mononuclear cells.
Pruvost A; Théodoro F; Agrofoglio L; Negredo E; Bénech H
J Mass Spectrom; 2008 Feb; 43(2):224-33. PubMed ID: 17935070
[TBL] [Abstract][Full Text] [Related]
35. Ultrasensitive method to quantify intracellular zidovudine mono-, di- and triphosphate concentrations in peripheral blood mononuclear cells by liquid chromatography-tandem mass spectrometry.
Kinai E; Gatanaga H; Kikuchi Y; Oka S; Kato S
J Mass Spectrom; 2015 Jun; 50(6):783-91. PubMed ID: 26169132
[TBL] [Abstract][Full Text] [Related]
36. Concentrations of zidovudine- and lamivudine-triphosphate according to cell type in HIV-seronegative adults.
Anderson PL; Zheng JH; King T; Bushman LR; Predhomme J; Meditz A; Gerber J; Fletcher CV
AIDS; 2007 Sep; 21(14):1849-54. PubMed ID: 17721092
[TBL] [Abstract][Full Text] [Related]
37. Simultaneous measurement of intracellular triphosphate metabolites of zidovudine, lamivudine and abacavir (carbovir) in human peripheral blood mononuclear cells by combined anion exchange solid phase extraction and LC-MS/MS.
Robbins BL; Poston PA; Neal EF; Slaughter C; Rodman JH
J Chromatogr B Analyt Technol Biomed Life Sci; 2007 May; 850(1-2):310-7. PubMed ID: 17197254
[TBL] [Abstract][Full Text] [Related]
38. Will cyclopentenyl cytosine (CPEC) ever have a future in the clinic?
van Bree C; van Kuilenburg AB
Leuk Res; 2008 Feb; 32(2):201-2. PubMed ID: 17681375
[No Abstract] [Full Text] [Related]
39. Sensitizing human colon carcinoma HT-29 cells to cisplatin by cyclopentenylcytosine, in vitro and in vivo.
Gharehbaghi K; Szekeres T; Yalowitz JA; Fritzer-Szekeres M; Pommier YG; Jayaram HN
Life Sci; 2000 Nov; 68(1):1-11. PubMed ID: 11132239
[TBL] [Abstract][Full Text] [Related]
40. Antitumor activity and biochemical effects of cyclopentenyl cytosine in mice.
Moyer JD; Malinowski NM; Treanor SP; Marquez VE
Cancer Res; 1986 Jul; 46(7):3325-9. PubMed ID: 3708566
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
